|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Cash and Marketable Securities held in Trust Account | ||||||||||||||
| Total Current Assets | ||||||||||||||
| Total Assets | ||||||||||||||
| LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accrued expenses | ||||||||||||||
| Accounts payable | ||||||||||||||
| Due to related party | ||||||||||||||
| Promissory note - related party | ||||||||||||||
| Deferred underwriting commissions | ||||||||||||||
| Total Current Liabilities | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 502,072 and 797,932 shares issued and outstanding at redemption value at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||
| Shareholders' Deficit | ||||||||||||||
| Ordinary shares | ||||||||||||||
| Class A ordinary shares | ||||||||||||||
| Total class A ordinary shares | ||||||||||||||
| Common Class B | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Total Shareholders' Deficit | ||||||||||||||
| TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT | ||||||||||||||
Loading...
